Finance

Lists
Why is HRMY up 3,09%?
Dive Deeper
HRMY:NASDAQ
Harmony Biosciences Holdings Inc
38,70 US$
+3,09%
(+1,16) 1D
38,87 US$
+0,44% (+0,17)
After hours
Closed: 20 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HRMY...
Open
37,99 US$
High
39,23 US$
Low
37,49 US$
Mkt. cap
2,25 მლრდ.
Avg. vol.
1,04 მლნ.
Volume
798,58 ათ.
P/E ratio
12,52
52-wk high
43,49 US$
52-wk low
25,81 US$
EPS
3,09 US$
Beta
1,01
Shares outstanding
58,24 მლნ.
No. of employees
293
Open
37,99 US$
High
39,23 US$
Low
37,49 US$
Mkt. cap
2,25 მლრდ.
Avg. vol.
1,04 მლნ.
Volume
798,58 ათ.
P/E ratio
12,52
52-wk high
43,49 US$
52-wk low
25,81 US$
EPS
3,09 US$
Beta
1,01
Shares outstanding
58,24 მლნ.
No. of employees
293
News stories
From web sources and news partners
About Harmony Biosciences Holdings Inc
CEO-
Employees293
Founded2017
Headquarters-
SectorPharmaceutical industry
Websiteharmonybiosciences.com
Analyst ratings
Based on 9 analysts giving stock ratings to HRMY in the past 3 months
Buy
Buy
5
Hold
3
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for HRMY in the last 3 months.
Highest
Current 38,70 US$
60,00 US$ (+55,04%)
Average
46,00 US$ (+18,86%)
Lowest
30,00 US$ (-22,48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ami Fadia
Needham
Buy
Reiterated
50,00 US$
+29,2%
10/19/2026
Caroline Palomeque
Ladenburg Thalmann & Co.
Buy
Initiated
55,00 US$
+42,1%
10/15/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
55,00 US$
+42,1%
10/13/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
51,00 US$
+31,8%
10/12/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
30,00 US$
-22,5%
10/12/2026
David Hoang
Deutsche Bank
Hold
Maintained
42,00 US$
+8,5%
10/01/2026
Rudy Li
Wolfe Research
Buy
Initiated
60,00 US$
+55%
08/26/2026
Danielle Brill
Truist Financial
Hold
Maintained
34,00 US$
-12,1%
08/05/2026
So Youn Shim
UBS
Hold
Maintained
37,00 US$
-4,4%
08/05/2026
Corinne Johnson
Goldman Sachs
Hold
Maintained
37,00 US$
-4,4%
07/16/2026
Jay Olson
Oppenheimer
Buy
Maintained
72,00 US$
+86%
04/22/2026
David Amsellem
Piper Sandler
Buy
Reiterated
46,00 US$
+18,9%
04/22/2026
Andreas Argyrides
Oppenheimer
Buy
Reiterated
62,00 US$
+60,2%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
239,46 მლნ.
243,78 მლნ.
215,39 მლნ.
261,28 მლნ.
Cost of goods sold
59,65 მლნ.
68,54 მლნ.
44,51 მლნ.
63,20 მლნ.
Cost of revenue
59,65 მლნ.
68,54 მლნ.
44,51 მლნ.
63,20 მლნ.
Research and development expenses
54,96 მლნ.
49,93 მლნ.
69,38 მლნ.
46,60 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
59,36 მლნ.
86,74 მლნ.
64,20 მლნ.
62,17 მლნ.
Operating expense
114,32 მლნ.
136,67 მლნ.
133,58 მლნ.
108,77 მლნ.
Total operating expenses
173,97 მლნ.
205,22 მლნ.
178,10 მლნ.
171,96 მლნ.
Operating income
65,49 მლნ.
38,56 მლნ.
37,29 მლნ.
89,32 მლნ.
Other non operating income
-106,00 ათ.
-105,00 ათ.
-127,00 ათ.
-53,00 ათ.
EBT including unusual items
67,49 მლნ.
40,76 მლნ.
39,69 მლნ.
93,26 მლნ.
EBT excluding unusual items
67,49 მლნ.
40,76 მლნ.
39,69 მლნ.
93,26 მლნ.
Income tax expense
16,62 მლნ.
18,27 მლნ.
7,20 მლნ.
17,83 მლნ.
Effective tax rate
24,63%
44,83%
18,14%
19,12%
Other operating expenses
-
-
-
-
Net income
50,86 მლნ.
22,49 მლნ.
32,49 მლნ.
75,43 მლნ.
Net profit margin
21,24%
9,22%
15,08%
28,87%
Earnings per share
1,08
0,57
0,79
1,50
Interest and investment income
5,73 მლნ.
5,85 მლნ.
5,76 მლნ.
7,07 მლნ.
Interest expense
-3,62 მლნ.
-3,55 მლნ.
-3,23 მლნ.
-3,07 მლნ.
Net interest expenses
2,11 მლნ.
2,31 მლნ.
2,52 მლნ.
4,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
71,46 მლნ.
45,99 მლნ.
43,26 მლნ.
95,28 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები